Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,764 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Chahoud J, et al. Among authors: sharma p. Oncologist. 2020 Mar;25(3):252-258. doi: 10.1634/theoncologist.2019-0372. Epub 2019 Sep 9. Oncologist. 2020. PMID: 32162795 Free PMC article.
Advances in the development of cancer immunotherapies.
Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Gao J, et al. Among authors: sharma p. Trends Immunol. 2013 Feb;34(2):90-8. doi: 10.1016/j.it.2012.08.004. Epub 2012 Sep 30. Trends Immunol. 2013. PMID: 23031830 Free PMC article. Review.
Harnessing the power of the immune system to target cancer.
Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Lizée G, et al. Among authors: sharma p. Annu Rev Med. 2013;64:71-90. doi: 10.1146/annurev-med-112311-083918. Epub 2012 Oct 22. Annu Rev Med. 2013. PMID: 23092383 Review.
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Liu XD, et al. Among authors: sharma p. Cancer Immunol Res. 2015 Sep;3(9):1017-29. doi: 10.1158/2326-6066.CIR-14-0244. Epub 2015 May 26. Cancer Immunol Res. 2015. PMID: 26014097 Free PMC article.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. Among authors: sharma p. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Antonia SJ, et al. Among authors: sharma p. Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269741 Free article. Clinical Trial.
11,764 results
You have reached the last available page of results. Please see the User Guide for more information.